[Search for the T790M mutation: The need to persevere]. / Recherche de la mutation T790M : savoir persévérer.
Rev Mal Respir
; 35(7): 731-737, 2018 Sep.
Article
in Fr
| MEDLINE
| ID: mdl-30115389
ABSTRACT
In cases of advanced EGFR mutation-positive non-small cell lung cancer, first or second generation EGFR-tyrosine kinase inhibitors (TKI-EGFR 1G or TKI-EGFR 2G) are recommended as first line treatment. Inexorably, progressive disease occurs and, in 50-60% of the cases, is secondary to a T790M resistant mutation. The prescription of osimertinib (TKI-EGFR3G) in second line is dependent on identification of the T790M mutation. We report 7 cases in which the identification of the T790M mutation required repeated analyses of cell free DNA and/or biopsies over a period of time. In some cases, a positive result was obtained a long time after progressive disease had been diagnosed during treatment with first or second generation EGFR-TKI. We discuss here the different modalities of screening for the T790M mutation and we encourage persevering in this search when no alternative mechanism of resistance has been identified.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
DNA Mutational Analysis
/
Carcinoma, Non-Small-Cell Lung
/
Drug Resistance, Neoplasm
/
Mutation, Missense
/
Lung Neoplasms
Type of study:
Prognostic_studies
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
Fr
Journal:
Rev Mal Respir
Year:
2018
Type:
Article
Affiliation country:
France